One platform connecting startups, corporations, research institutions, regions and investors
Playbook & Handbook · February 6, 2026
Winning Accelerator Playbook 2026 by BambuUP
EDTECH: LEVERAGING AI-POWERED TECHNOLOGIES TO TRANSFORM THE LEARNING EXPERIENCE
1. Technology overview
RetinAI is operated by Ikerian AG in Bern, Switzerland, with a U.S. entity in Boston. The company builds software for ophthalmic imaging data management and AI analysis, serving clinics, pharma sponsors and research groups.
The Discovery platform is vendor-neutral and accepts DICOM and proprietary formats from many imaging devices. Variants cover clinics, clinical studies and real-world evidence, with AI models such as the CE-marked OCT Atlas for AMD, DR, DME and glaucoma, and LuxIA for diabetic retinopathy screening. Customers named on the site include Novartis, Isarna Therapeutics and OcuTerra.
2. Highlighted features & specifications
- Discovery for Clinics: Vendor-neutral imaging management and AI analysis for eye clinics.
- OCT Atlas: CE-marked AI model covering AMD, DR, DME and glaucoma.
- LuxIA: AI-based diabetic retinopathy screening algorithm with CE-MDR certification.
- Clinical studies module: Imaging endpoints and biomarker analysis for trials.
- Real World Evidence: Aggregated imaging data analytics for pharma.
- Disease evaluation apps: Task-specific apps and a CONNECT feature for data exchange.
3. Potential application
Private eye hospitals in Vietnam can consolidate OCT archives from several devices. Retina centers can track AMD progression with AI measurements. Research groups can use imaging endpoints in local clinical studies.
4. Benefits
Centralizes OCT and fundus data from different device brands in one vendor-neutral platform.
CE-marked AI models support AMD, DR, DME and glaucoma assessment in clinics.
Supports pharma trials with imaging biomarkers and real-world evidence workflows.
Holds EU MDR certification, ISO 13485, HIPAA and GDPR compliance.
5. Market trends & opportunities
Ophthalmology generates large OCT and fundus datasets, and clinics and pharma sponsors want AI-ready, vendor-neutral platforms. In Southeast Asia, growing retina disease burden and OCT adoption create demand for imaging management and AI-assisted reading.
6. Other information
Operated by Ikerian AG (Bern, Switzerland), RetinAI U.S. Inc. in Boston. EU-MDR certificate announced June 2024 for devices, data platform and AI models; LuxIA CE-MDR announced April 2025. Collaboration with PulseSight Therapeutics expanded October 2026.
